Microbot Medical Inc (MBOT)vsWest Pharmaceutical Services Inc (WST)
MBOT
Microbot Medical Inc
$1.84
-6.12%
HEALTHCARE · Cap: $132.99M
WST
West Pharmaceutical Services Inc
$314.50
-0.89%
HEALTHCARE · Cap: $23.23B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 3067519% more annual revenue ($3.22B vs $105,000). WST leads profitability with a 16.9% profit margin vs 0.0%. MBOT appears more attractively valued with a PEG of 0.70. WST earns a higher WallStSmart Score of 65/100 (C+).
MBOT
Avoid34
out of 100
Grade: F
WST
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MBOT.
Margin of Safety
-56.0%
Fair Value
$157.79
Current Price
$314.50
$156.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 56.1% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 21.7%
Revenue surging 21.0% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MBOT
The strongest argument for MBOT centers on Debt/Equity, Altman Z-Score, PEG Ratio. PEG of 0.70 suggests the stock is reasonably priced for its growth.
Bull Case : WST
The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.
Bear Case : MBOT
The primary concerns for MBOT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : WST
The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.
Key Dynamics to Monitor
MBOT profiles as a value stock while WST is a growth play — different risk/reward profiles.
WST carries more volatility with a beta of 1.18 — expect wider price swings.
WST is growing revenue faster at 21.0% — sustainability is the question.
WST generates stronger free cash flow (47M), providing more financial flexibility.
Bottom Line
WST scores higher overall (65/100 vs 34/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Microbot Medical Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Microbot Medical Inc., a preclinical medical device company, researches, designs and develops micro-robotic-assisted medical technologies targeting the minimally invasive surgery space. The company is headquartered in Hingham, Massachusetts.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?